Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy

Samuel J Taylor; Wallace Y Langdon

doi:10.1080/23723556.2017.1378156

Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy

Mol Cell Oncol. 2017 Sep 19;4(6):e1378156. doi: 10.1080/23723556.2017.1378156. eCollection 2017.

Authors

Samuel J Taylor¹, Wallace Y Langdon¹

Affiliation

¹ Department of Pathology and Laboratory Medicine, School of Biomedical Sciences, University of Western Australia, Crawley, Western Australia, Australia.

Abstract

Myelosuppression is one of the most severe and limiting side effects of chemotherapy. Our recent work outlines a strategy to prevent chemotherapy-induced myelosuppression by administering a priming dose of the FMS-Like Tyrosine kinase 3 (FLT3) inhibitor quizartinib. Furthermore, by administering sequential quizartinib primed injections of fluorouracil (5-FU), we demonstrated a novel and effective strategy to eliminate disease in two mouse models of quizartinib resistant acute myeloid leukemia (AML).

Keywords: FLT3; acute myeloid leukemia; chemotherapy; hematopoietic progenitors; myelosuppression; quizartinib.